Small Molecule Compounds Modulating Inflammatory Bowel Disease Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) primarily focus on systemic inflammation suppression rather than addressing the underlying condition, leading to incomplete recovery and potential complications.
Innovation Solution
Development of small molecule-based compounds, such as compound A, compound B, and others, which are used to create pharmaceutical compositions and dosage units for treating IBD. These compounds are designed to modulate specific inflammatory pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic inflammation suppression approaches are used, then inflammation is reduced, but the underlying condition is not treated and incomplete recovery occurs
Solution Approach 1:
The patent extracts and targets specific underlying mechanisms of IBD (such as microbial translocation, specific cytokine pathways, and gut barrier dysfunction) rather than treating systemic inflammation generally. This allows direct intervention in the root causes while maintaining anti-inflammatory effects.
Solution Approach 2:
The compounds provide localized action at specific pathways and tissue levels (gut barrier, mucosal lining, specific immune cells) rather than systemic suppression. This targeted approach treats the underlying condition at its source while reducing harmful inflammation effects.
2Measurement precision
If small molecule-based compounds are developed, then treatment specificity is improved, but development complexity increases
Solution Approach 1:
The patent segments the complex IBD pathophysiology into distinct targetable mechanisms (microbial translocation, specific cytokine signaling, gut barrier integrity) and develops compounds针对 each specific pathway. This modular approach enables precise treatment while managing development complexity through focused research areas.
Solution Approach 2:
The small molecule compounds modify specific molecular parameters and interaction mechanisms (binding affinities, signaling pathway activation, membrane permeability) to achieve high treatment specificity. By optimizing these molecular parameters, the patent achieves precise targeting without requiring complex delivery systems.
Data Source
AI summary
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.